期刊文献+

HBP、IL-17A、IL-17F等炎性因子在小儿脓毒症早期诊断中的价值对比研究 被引量:3

Comparative research of inflame factors such as HBP,IL-17A,IL-17F in child patients with sepsis
原文传递
导出
摘要 目的比较脓毒症前不同时间点肝素结合蛋白等炎性因子的诊断效能。方法选取2014年1月-2016年10月本院小儿脓毒症患者24例,收集其诊断脓毒症的时刻0 h、前24 h、前48 h、前72 h血浆,同期选取22例无器质性疾病的健康体检者抽取血浆作为对照组,酶联免疫吸附法检测HBP、IL-17A、IL-17F。结果 HBP在前48 h、24 h、0 h时间点均高于其前一时间点水平(P<0.01),所有时间点均高于对照组(P<0.01)。受试者工作特征曲线(ROC曲线)显示,HBP在前72 h、前48 h、前24 h、0 h的AUC分别为0.823、0.898、0.935、1.000,但只有前72 h明显高于其他2种细胞因子。结论 HBP具有较宽的诊断窗口期,适合作为小儿脓毒症的早期预测指标。 Objective To compare the diagnostic efficacy of inflammatory factors such as heparin-binding protein( HBP) at different time points before the incidence of sepsis. Methods 24 child patients with sepsis from January 2014 to October 2016 were selected. Blood samples were collected at 0 h,24 h,48 h,72 h before the diagnosis of sepsis,and 22 healthy volunteers without organic disease were selected as the control group and their plasma was taken during the same period. Enzyme-linked immunosorbent assay was used to detect HBP,IL-17 A,IL-17 F. Results The serum levels of HBP at all time points were all higher than that at the former point,and significantly higher than the control group( P〈 0. 01). Receiver operating characteristic curve( ROC) revealed that the areas at 72 h,48 h,24 h,0 h before the diagnosis time were 0. 823,0. 898,0. 935,1. 000,but only that at 72 h was higher than the other 2 interleukins. Conclusion HBP has a wide diagnostic window period for sepsis,which is suitable as an early predictor of pediatric sepsis.
出处 《中国卫生检验杂志》 CAS 2018年第3期303-305,308,共4页 Chinese Journal of Health Laboratory Technology
基金 浙江省医药卫生科研基金项目(2015KYA228)
关键词 肝素结合蛋白 白介素 脓毒症 Heparin - binding protein Interleukin ANIT Sepsis
  • 相关文献

参考文献7

二级参考文献66

  • 1樊寻梅,武志远.国际儿科脓毒症定义会议介绍[J].中华儿科杂志,2005,43(8):618-620. 被引量:90
  • 2胡洁勇.血清C反应蛋白与前白蛋白的测定在新生儿感染性疾病中的应用价值[J].山西医科大学学报,2007,38(2):162-164. 被引量:16
  • 3胡凤华,甘小庄,孙丽萍,郭琳英,李杰,任晓旭,崔小岱,宋国维.脓毒症患儿降钙素原测定的临床意义[J].实用儿科临床杂志,2007,22(6):412-413. 被引量:15
  • 4董培红,李骥,张慧芳,张友才,王邦松.铜绿假单胞菌的临床分布和耐药性变迁[J].中国微生态学杂志,2007,19(5):452-454. 被引量:26
  • 5Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis, 2007, 7 (1): 10.
  • 6Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine, 2011, 9( 1) : 107.
  • 7Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Hespir Crit Care Med, 2008, 177(5): 498-505.
  • 8Bouadma L, Luyt CE, Tubach F, et al. PRORATA trial group: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet, 2010, 375 (9713): 463474.
  • 9Christ-Crain M, Stolz D, Bingisser R. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med, 2006, 174(1) : 84-93.
  • 10Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin -guided treatment on antibiotic use and outcome in lower respiratory tract infections: clusterrandomised, singleblinded intervention trial. Lancet, 2004, 363(9409): 600-607.

共引文献225

同被引文献26

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部